Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling

John T. Vetto, Eddy C. Hsueh, Brian R. Gastman, Larry D. Dillon, Federico A. Monzon, Robert W. Cook, Jennifer Keller, Xin Huang, Andrew Fleming, Preston Hewgley, Pedram Gerami, Sancy Leachman, Jeffrey D. Wayne, Adam C. Berger, Martin D. Fleming

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.

Original languageEnglish (US)
Pages (from-to)1207-1217
Number of pages11
JournalFuture Oncology
Volume15
Issue number11
DOIs
StatePublished - Apr 2019

Keywords

  • biomarker
  • gene expression profiling
  • melanoma
  • prognosis
  • sentinel lymph node biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling'. Together they form a unique fingerprint.

  • Cite this

    Vetto, J. T., Hsueh, E. C., Gastman, B. R., Dillon, L. D., Monzon, F. A., Cook, R. W., Keller, J., Huang, X., Fleming, A., Hewgley, P., Gerami, P., Leachman, S., Wayne, J. D., Berger, A. C., & Fleming, M. D. (2019). Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncology, 15(11), 1207-1217. https://doi.org/10.2217/fon-2018-0912